중피종

June 2, 2023

Hess Corp, 중피종 피해자를 위한 합의에 도달

After years of litigation, the Hess Corporation agreed to settle hundreds of asbestos exposure lawsuits filed on the island of St. Croix. The company will establish a $106 million trust for victims, their surviving family members, and those that may be diagnosed in the future. A Hess-owned oil refinery operated on the island from 1965 to 1998, and exposed workers and people staying on the island to asbestos and benzene. Hess will provide $90 million in compensation for mesothelioma and other claimants who have filed for compensation. An additional $15 million is being set aside to benefit those who may be […]
March 14, 2023

폐암 백신: 중피종 백신으로 이어질 수 있습니까?

CIMAvax-EGF is a new lung cancer treatment that “harnesses the body’s immune system to fight lung cancer.” They began testing the drug in 2017; another trial is testing the drug for the prevention of lung cancer in patients who are at high risk. CIMAvax-EGF blocks a certain protein (epidermal growth factor (EGF)) that cancer cells need to grow. The drug works by starving the cancer cells by preventing EGF from attaching to the cell. If the cancer cell cannot multiply, it dies. They have treated more than 5,000 lung cancer patients so far with this unique immunotherapy. Several international studies […]
January 10, 2023

Base Editing은 중피종 치료의 미래입니까?

Base editing is a revolutionary technology that has the potential to revolutionize the treatment of mesothelioma. This technology allows scientists to make precise, targeted changes to a patient’s genetic code, without introducing any foreign DNA into the patient’s body. This technology has the potential to be used to treat cancer and other genetic diseases. A young patient with leukemia is now clear of the cancer after base editing therapy. In the future, base editing could be used to create personalized treatments for mesothelioma. By analyzing a patient’s genetic code, doctors could determine the best approach to treating their mesothelioma. This […]
September 27, 2022

새로운 중피종 약물 시험 시작

Verismo Therapeutics announced that is has received clearance of its new drug for ovarian cancer, cholangiocarcinoma, and, mesothelioma from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110. The first human trials are set to start soon. They will “address several areas of high unmet medical need.” The five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma and 10% for mesothelioma. The FDA’s clearance of the new drug represents a new for mesothelioma treatments and innovative research. Verismo plans to begin enrolling patients in the first quarter of 2023 at […]
April 5, 2022

중피종의 오진이 왜 그렇게 흔합니까?

Whether it is primary exposure due to working directly with the dangerous material or secondary exposure suffered by friends and family, contact with asbestos fibers can lead to devastating, deadly conditions. Unfortunately, it is not uncommon for medical professionals to incorrectly diagnose mesothelioma, asbestosis or lung cancer when early symptoms become apparent. While every situation is unique, there are numerous factors that can dramatically impact the speed and accuracy of a medical diagnosis for mesothelioma, including: Symptom overlap: Unfortunately, mesothelioma shares numerous symptoms with other lung conditions that range in seriousness. This can make it challenging for a medical professional […]
February 18, 2022

중피종 진단에서 성별의 역할

The stereotype of a mesothelioma patient is an older male who plied a trade over decades that exposed him to asbestos. In fact, many women receive these life-changing diagnoses. The disease does not discriminate. A recent study reveals the different dynamics between the genders, their specific needs, and how they deal with an uncertain and [...]
February 18, 2022

인공지능의 출현

A cure for malignant mesothelioma remains elusive and is considered one of the most challenging to measure with CT scans due to characteristically complex growth patterns. However, scientists based in Scotland – a country near the top of mesothelioma incidence rates – may have found a way to radically change treating the life-changing, deadly disease. [...]
June 2, 2023

Hess Corp, 중피종 피해자를 위한 합의에 도달

After years of litigation, the Hess Corporation agreed to settle hundreds of asbestos exposure lawsuits filed on the island of St. Croix. The company will establish a $106 million trust for victims, their surviving family members, and those that may be diagnosed in the future. A Hess-owned oil refinery operated on the island from 1965 to 1998, and exposed workers and people staying on the island to asbestos and benzene. Hess will provide $90 million in compensation for mesothelioma and other claimants who have filed for compensation. An additional $15 million is being set aside to benefit those who may be […]
March 14, 2023

폐암 백신: 중피종 백신으로 이어질 수 있습니까?

CIMAvax-EGF is a new lung cancer treatment that “harnesses the body’s immune system to fight lung cancer.” They began testing the drug in 2017; another trial is testing the drug for the prevention of lung cancer in patients who are at high risk. CIMAvax-EGF blocks a certain protein (epidermal growth factor (EGF)) that cancer cells need to grow. The drug works by starving the cancer cells by preventing EGF from attaching to the cell. If the cancer cell cannot multiply, it dies. They have treated more than 5,000 lung cancer patients so far with this unique immunotherapy. Several international studies […]
January 10, 2023

Base Editing은 중피종 치료의 미래입니까?

Base editing is a revolutionary technology that has the potential to revolutionize the treatment of mesothelioma. This technology allows scientists to make precise, targeted changes to a patient’s genetic code, without introducing any foreign DNA into the patient’s body. This technology has the potential to be used to treat cancer and other genetic diseases. A young patient with leukemia is now clear of the cancer after base editing therapy. In the future, base editing could be used to create personalized treatments for mesothelioma. By analyzing a patient’s genetic code, doctors could determine the best approach to treating their mesothelioma. This […]
September 27, 2022

새로운 중피종 약물 시험 시작

Verismo Therapeutics announced that is has received clearance of its new drug for ovarian cancer, cholangiocarcinoma, and, mesothelioma from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110. The first human trials are set to start soon. They will “address several areas of high unmet medical need.” The five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma and 10% for mesothelioma. The FDA’s clearance of the new drug represents a new for mesothelioma treatments and innovative research. Verismo plans to begin enrolling patients in the first quarter of 2023 at […]
April 5, 2022

중피종의 오진이 왜 그렇게 흔합니까?

Whether it is primary exposure due to working directly with the dangerous material or secondary exposure suffered by friends and family, contact with asbestos fibers can lead to devastating, deadly conditions. Unfortunately, it is not uncommon for medical professionals to incorrectly diagnose mesothelioma, asbestosis or lung cancer when early symptoms become apparent. While every situation is unique, there are numerous factors that can dramatically impact the speed and accuracy of a medical diagnosis for mesothelioma, including: Symptom overlap: Unfortunately, mesothelioma shares numerous symptoms with other lung conditions that range in seriousness. This can make it challenging for a medical professional […]
February 18, 2022

중피종 진단에서 성별의 역할

The stereotype of a mesothelioma patient is an older male who plied a trade over decades that exposed him to asbestos. In fact, many women receive these life-changing diagnoses. The disease does not discriminate. A recent study reveals the different dynamics between the genders, their specific needs, and how they deal with an uncertain and [...]
February 18, 2022

인공지능의 출현

A cure for malignant mesothelioma remains elusive and is considered one of the most challenging to measure with CT scans due to characteristically complex growth patterns. However, scientists based in Scotland – a country near the top of mesothelioma incidence rates – may have found a way to radically change treating the life-changing, deadly disease. [...]